Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $118.10 Consensus PT from Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have received a consensus rating of “Moderate Buy” from the twenty-three brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $118.0952.

A number of analysts recently issued reports on KYMR shares. Stephens boosted their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. Piper Sandler increased their target price on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Morgan Stanley restated an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research report on Thursday, April 30th. UBS Group raised their price target on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Finally, Canaccord Genuity Group initiated coverage on shares of Kymera Therapeutics in a research report on Wednesday, May 6th. They issued a “buy” rating and a $106.00 price target for the company.

Kymera Therapeutics Stock Down 2.7%

NASDAQ:KYMR opened at $82.21 on Wednesday. Kymera Therapeutics has a 52 week low of $28.06 and a 52 week high of $103.00. The business’s 50-day simple moving average is $83.58 and its two-hundred day simple moving average is $77.93. The stock has a market cap of $6.76 billion, a PE ratio of -23.03 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. During the same period in the previous year, the firm posted ($0.82) earnings per share. The business’s revenue was up 55.5% compared to the same quarter last year. Sell-side analysts anticipate that Kymera Therapeutics will post -3.34 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Bruce Booth sold 81,866 shares of Kymera Therapeutics stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $90.13, for a total value of $7,378,582.58. Following the sale, the director owned 675,341 shares of the company’s stock, valued at $60,868,484.33. The trade was a 10.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Bruce N. Jacobs sold 7,576 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $88.93, for a total transaction of $673,733.68. Following the completion of the transaction, the chief financial officer directly owned 237,483 shares of the company’s stock, valued at approximately $21,119,363.19. This represents a 3.09% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 383,734 shares of company stock valued at $32,454,902 in the last quarter. Corporate insiders own 15.98% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. US Bancorp DE raised its position in shares of Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after purchasing an additional 166 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Kymera Therapeutics by 9.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock valued at $156,000 after purchasing an additional 248 shares during the period. Cetera Investment Advisers increased its stake in Kymera Therapeutics by 7.5% during the 1st quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock worth $300,000 after purchasing an additional 252 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of Kymera Therapeutics by 36.9% during the 4th quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after acquiring an additional 287 shares in the last quarter. Finally, Swiss National Bank grew its stake in shares of Kymera Therapeutics by 0.3% in the first quarter. Swiss National Bank now owns 94,500 shares of the company’s stock valued at $7,871,000 after buying an additional 300 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.